What is the role of specific B cell subsets in different disease contexts?

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is ... This type of activation produces memory and plasma B cells. Naïve B cells bind to soluble or membrane bound antigens and internalize the antigen. The B cell ... DLBCL is a common type of fast growing (high grade) NHL. Lymphoma develops when white blood cells called lymphocytes grow out of control. Screening for common variable immunodeficiency and hyper-IgM syndromes. Assessing B-cell subset reconstitution after stem cell or bone marrow transplant. Oct 11, 2016 ... ... B cells during pathogenic secondary DENV infections is needed. This ... B cells yield plasmablasts and plasma cells (Seifert et al., 2015. Sep 7, 2017 ... The US Food and Drug Administration granted regular approval to tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) for the treatment of patients up to ... Jun 12, 2024 ... INTRODUCTION. B cell prolymphocytic leukemia (B-PLL) is a very rare B cell neoplasm comprised of so-called prolymphocytes, typically with ... Feb 1, 2023 ... B Cells. B cells protect you from infection by making proteins called antibodies. B cells are a type of white blood cell called lymphocytes. A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile. Dec 1, 2018 ... The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas.